Investor Relations

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending December 31, 2023

Company Overview

Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

Stock Snapshot

IR Contacts

Headquarters

Sutro Biopharma, Inc.
111 Oyster Point Blvd
South San Francisco, CA 94080

Investor Relations

Sutro Biopharma
Emily White
Investor Relations and Communications Advisor
T: 650-823-7681
ewhite@sutrobio.com